DA
Therapeutic Areas
Oncopeptides Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Pepaxti (melphalan flufenamide) | Multiple Myeloma (triple-class refractory) | Approved |
| Pepaxti | Multiple Myeloma (earlier lines) | Phase 3 |
| OPC-001 (PDC Candidate) | Glioblastoma | Phase 1/Window-of-Opportunity |
| SPiKE Platform Candidates | Undisclosed Hematological/Solid Tumors | Preclinical |